Exvastat is an innovative, clinical-stage pharmaceutical company founded in 2016. The company is developing a treatment for acute respiratory distress syndrome (ARDS) based on a reformulation of imatinib (Impentri©) which is marketed worldwide as an oral treatment for chronic myeloid leukemia. The new treatment is based on the drug’s ability to inhibit vascular leak, which drives the pulmonary oedema, and has been found to be effective in a number of human case reports as well as in vivo models (see here).
Impentri has the potential to significantly reduce the high mortality and incapacitating morbidities caused by ARDS, as well as the costs of caring for these critically ill patients to health service providers. ARDS currently lacks any approved pharmaceutical therapy, with treatment limited to supportive ventilatory care.